Development of a Practical Synthesis of a TORC1/2 Inhibitor: A Scalable Application of Memory of Chirality

Progression toward a scalable synthesis of TORC1/2 inhibitor bulk drug, culminating in the first GMP manufacturing campaign, is described. Process research and development was needed to obtain the prerequisite stereocenter in high enantiomeric excess for kilogram-scale production. Through route selection, a six-linear step synthesis was developed which afforded the API in 20% overall yield. Development included an application of memory of chirality (MOC) to install a quaternary chiral center with near complete retention, a reductive cyclization to form a piperazinone core, and a palladium-catalyzed C–C bond-forming step.

[1]  H. Blaser,et al.  Strong reduction of hydroxylamine accumulation in the catalytic hydrogenation of nitroarenes by vanadium promoters , 1997 .

[2]  N. Sonenberg,et al.  Upstream and downstream of mTOR. , 2004, Genes & development.

[3]  U. McDermott,et al.  Discovery of a benzo[e]pyrimido-[5,4-b][1,4]diazepin-6(11H)-one as a Potent and Selective Inhibitor of Big MAP Kinase 1 , 2011, ACS medicinal chemistry letters.

[4]  T. Kawabata,et al.  Stereochemical diversity in asymmetric cyclization via memory of chirality. , 2006, Journal of the American Chemical Society.

[5]  Michael N. Hall,et al.  TOR signalling in bugs, brain and brawn , 2003, Nature Reviews Molecular Cell Biology.

[6]  M. Radi,et al.  ATP-competitive inhibitors of mTOR: an update. , 2011, Current medicinal chemistry.

[7]  M. Hall,et al.  TOR Signaling in Growth and Metabolism , 2006, Cell.

[8]  M. Yar,et al.  Bromoethylsulfonium salt--a more effective annulation agent for the synthesis of 6- and 7-membered 1,4-heterocyclic compounds. , 2009, Organic letters.

[9]  M. Yar,et al.  An annulation reaction for the synthesis of morpholines, thiomorpholines, and piperazines from beta-heteroatom amino compounds and vinyl sulfonium salts. , 2008, Angewandte Chemie.

[10]  D. Sabatini,et al.  mTOR: from growth signal integration to cancer, diabetes and ageing , 2010, Nature Reviews Molecular Cell Biology.

[11]  M. Guba,et al.  Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis , 2007, Cancer and Metastasis Reviews.

[12]  P. Smolewski.  Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway , 2006, Anti-cancer drugs.

[13]  M. Agulnik.  New Developments in Mammalian Target of Rapamycin Inhibitors for the Treatment of Sarcoma , 2011, Cancer.